Literature DB >> 6128918

Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients.

J Staessen, C Bulpitt, A Cattaert, R Fagard, L Vanhees, A Amery.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128918     DOI: 10.1016/0002-8703(82)90184-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  6 in total

Review 1.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

2.  Beta blockers after myocardial infarction: have trials changed practice?

Authors:  N S Baber; D G Julian; J A Lewis; G Rose
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

3.  Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.

Authors: 
Journal:  Postgrad Med J       Date:  1984-02       Impact factor: 2.401

4.  Effects of chronic metoprolol and sulphinpyrazone on human lymphocyte beta-adrenoceptors.

Authors:  A De Blasi; M Cortellaro; C Costantini
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

5.  Starting Antihypertensive Drug Treatment With Combination Therapy: Controversies in Hypertension - Con Side of the Argument.

Authors:  Zhen-Yu Zhang; Yu-Ling Yu; Kei Asayama; Tine W Hansen; Gladys E Maestre; Jan A Staessen
Journal:  Hypertension       Date:  2021-02-10       Impact factor: 10.190

6.  Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients.

Authors:  Qi-Fang Huang; Jan Van Keer; Zhen-Yu Zhang; Sander Trenson; Esther Nkuipou-Kenfack; Lucas N L Van Aelst; Wen-Yi Yang; Lutgarde Thijs; Fang-Fei Wei; Agnieszka Ciarka; Johan Vanhaecke; Stefan Janssens; Johan Van Cleemput; Harald Mischak; Jan A Staessen
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.